Results 231 to 240 of about 13,250,277 (360)

Apolipoprotein B (B-46)

open access: yesBiomedicine & Pharmacotherapy, 1990
openaire   +2 more sources

GREM1 deficiency induced bone marrow adipose niche promotes B‐cell acute lymphoblastic leukemia disease progression

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Too often, children treated for B‐cell acute lymphocytic leukemia (B‐ALL) experience relapse. Here, the authors investigate the role of dyslipidemia in leukemia progression. Higher adipogenicity in bone marrow mesenchymal stem cells, and increased triglyceride accumulation, are associated with higher risk of death.
Lili Song   +10 more
wiley   +1 more source

Effects of a Multimodal Lifestyle Intervention on Cardiometabolic Markers in People with Progressive Multiple Sclerosis: A Secondary Analysis of a Pilot Study. [PDF]

open access: yesNutrients
Martinez AS   +10 more
europepmc   +1 more source

Sex‐specific associations of Roseburia with uric acid metabolism and hyperuricemia risk in females

open access: yesiMetaOmics, EarlyView.
Researchers recruited 623 participants, including 270 females, and used 16S rDNA sequencing to investigate gender differences in hyperuricemia. In healthy females, Roseburia was enriched, positively correlating with estrogen and negatively with uric acid, suggesting it is a potential biomarker affecting uric acid levels in females.
Zhihan Yang   +8 more
wiley   +1 more source

Studies on the Apolipoproteins and Lipoproteins of Cord Serum

open access: yesPediatric Research, 1980
W. Mcconathy, Daniel M Lake
semanticscholar   +1 more source

Structural organization of apolipoprotein B-100 of human plasma low density lipoproteins. Comparison to B-48 of chylomicrons and very low density lipoproteins.

open access: hybrid, 1986
A D Cardin   +6 more
openalex   +1 more source

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Fenofibrate is contraindicated in patients with advanced hepatic fibrosis due to limited clinical data. We evaluated the pharmacokinetics and safety of fenofibrate in participants with mild hepatic impairment (phase 1 study) or advanced fibrosis due to metabolic‐associated fatty liver disease (MAFLD; phase 2a study).
Islam R. Younis   +5 more
wiley   +1 more source

Plasma apolipoproteins and risk for age related maculopathy

open access: yesBritish Journal of Ophthalmology, 2006
N. Dashti   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy